Silo Pharma Commences Study Of Novel Joint Homing Peptide SPU-21
Portfolio Pulse from Happy Mohamed
Silo Pharma (NASDAQ:SILO) has commenced a study of its novel joint homing peptide SPU-21 targeting rheumatoid arthritis. The Phase 2 study will investigate the peptides' method, optimization, and binding affinity in human tissue. The company is collaborating with the University of Maryland, Baltimore.
May 30, 2023 | 1:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silo Pharma has started a Phase 2 study of its joint homing peptide SPU-21 for rheumatoid arthritis, working with the University of Maryland, Baltimore.
The commencement of the Phase 2 study of SPU-21 indicates progress in Silo Pharma's research and development efforts. This could potentially lead to a new treatment for rheumatoid arthritis, which would be a significant milestone for the company. The collaboration with the University of Maryland, Baltimore, adds credibility to the project. This news is likely to have a positive short-term impact on SILO's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100